Current Report Filing (8-k)
July 14 2017 - 5:07PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 13, 2017
ANTHERA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
001-34637
|
|
20-1852016
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
25801 Industrial Boulevard, Suite B, Hayward,
California
|
|
94545
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 13, 2017, Chuck Olson tendered his letter of resignation from the role of
Senior Vice President, Chief Technology Officer, effective July 13, 2017. Dr. Olson will continue to be available to the Company in an advisory role with respect to the Company’s manufacturing strategy.
On July 13, 2017, Dr. Renee Martin, Ph.D., who joined the Company in March 2010 and is currently serving as the Company’s Senior Vice President, Medical Science, will assume functional leadership for the Company’s manufacturing strategy which complements and expands her background
of scientific research
.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 14, 2017
|
Anthera Pharmaceuticals, Inc.
|
|
|
|
|
|
|
By:
|
/s/ May Liu
|
|
|
May Liu
|
|
|
Senior Vice President, Finance and
|
|
|
Administration
|
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Sep 2023 to Sep 2024